BIOAGE LABS INC (BIOA) Stock Price & Overview
NASDAQ:BIOA • US09077V1008
Current stock price
The current stock price of BIOA is 18.06 USD. Today BIOA is up by 5.92%. In the past month the price increased by 11.83%. In the past year, price increased by 331.03%.
BIOA Key Statistics
- Market Cap
- 801.503M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.24
- Dividend Yield
- N/A
BIOA Stock Performance
BIOA Stock Chart
BIOA Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to BIOA. When comparing the yearly performance of all stocks, BIOA is one of the better performing stocks in the market, outperforming 98.11% of all stocks.
BIOA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BIOA. No worries on liquidiy or solvency for BIOA as it has an excellent financial health rating, but there are worries on the profitability.
BIOA Earnings
On March 24, 2026 BIOA reported an EPS of -0.72 and a revenue of 3.08M. The company beat EPS expectations (4.46% surprise) and beat revenue expectations (115.85% surprise).
BIOA Forecast & Estimates
13 analysts have analysed BIOA and the average price target is 45.39 USD. This implies a price increase of 151.33% is expected in the next year compared to the current price of 18.06.
For the next year, analysts expect an EPS growth of -18.45% and a revenue growth 917.54% for BIOA
BIOA Groups
Sector & Classification
BIOA Financial Highlights
Over the last trailing twelve months BIOA reported a non-GAAP Earnings per Share(EPS) of -2.24. The EPS decreased by -13.09% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -27.33% | ||
| ROE | -29.63% | ||
| Debt/Equity | 0 |
BIOA Ownership
BIOA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 24.83 | 835.183B | ||
| JNJ | JOHNSON & JOHNSON | 17.76 | 547.959B | ||
| MRK | MERCK & CO. INC. | 21.65 | 276.38B | ||
| PFE | PFIZER INC | 8.96 | 153.586B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.13 | 119.871B | ||
| ZTS | ZOETIS INC | 16.67 | 49.146B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.61 | 28.489B | ||
| VTRS | VIATRIS INC | 5.94 | 16.989B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 20.99 | 11.361B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.512B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.104B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.05B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.18 | 4.899B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BIOA
Company Profile
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. The company is headquartered in Emeryville, California and currently employs 62 full-time employees. The company went IPO on 2024-09-26. Its lead product is BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration. In preclinical obesity models, BGE-102 resulted in weight loss as both a monotherapy and in combination with a GLP-1R agonist. Its pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. In preclinical obesity models, APJ agonism has demonstrated the ability to more than double the weight loss induced by a GLP-1R agonist while also restoring healthy body composition and improving muscle function.
Company Info
IPO: 2024-09-26
BIOAGE LABS INC
5885 Hollis Street, Suite 370
Emeryville CALIFORNIA H3B 4W8 US
CEO: Fabrice Orecchioni
Employees: 61
Phone: 18002462677
BIOAGE LABS INC / BIOA FAQ
What does BIOAGE LABS INC do?
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. The company is headquartered in Emeryville, California and currently employs 62 full-time employees. The company went IPO on 2024-09-26. Its lead product is BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration. In preclinical obesity models, BGE-102 resulted in weight loss as both a monotherapy and in combination with a GLP-1R agonist. Its pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. In preclinical obesity models, APJ agonism has demonstrated the ability to more than double the weight loss induced by a GLP-1R agonist while also restoring healthy body composition and improving muscle function.
What is the stock price of BIOAGE LABS INC today?
The current stock price of BIOA is 18.06 USD. The price increased by 5.92% in the last trading session.
Does BIOA stock pay dividends?
BIOA does not pay a dividend.
How is the ChartMill rating for BIOAGE LABS INC?
BIOA has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the sector and industry classification for BIOAGE LABS INC?
BIOAGE LABS INC (BIOA) operates in the Health Care sector and the Pharmaceuticals industry.
How is the valuation of BIOAGE LABS INC (BIOA) based on its PE ratio?
BIOAGE LABS INC (BIOA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.24).
Can you provide the upcoming earnings date for BIOAGE LABS INC?
BIOAGE LABS INC (BIOA) will report earnings on 2026-05-12.